Advertisement
Advertisement
http://www.eahad2015.com

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant - An in-vivo study

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH06-10-0562
Issue: 2007: 97/6 (June) pp. 873-1060
Pages: 1037-1045

A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant - An in-vivo study

Janusz Szemraj1, Adrian Stankiewicz2, Wioletta Rozmyslowicz-Szermi¡ska2, Andrzej Mogielnicki3, Anna Gromotowicz2, Wlodzimierz Buczko3, Katarzyna Oszajca1, Jacek Bartkowiak 1, Ewa Chabielska2
1Department of Medical Biochemistry, Medical University of Lódˆ, Lódˆ, Poland; 2Department of Biopharmacy and 3Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland

Keywords

Venous thrombosis, Arterial thrombosis, Recombinant protein, antiplatelet activity, thrombolytic agent

Summary

The recombinant protein SAK-RGD-K2-Hir is characterized by its fibrin-specific properties of plasminogen activation combined with antithrombin and antiplatelet activities. It was previously shown in our in-vitro studies to be a more potent and faster-acting thrombolytic agent compared with standard r-SAK. In order to document the effects of the thrombolytic potential of SAKRGD- K2-Hir we examined this protein in an electrically induced carotid artery thrombosis model and stasis-induced venous model in rats. In the arterial thrombosis model, a bolus injection of SAK-RGD-K2-Hir was less effective than rt-PA and r-SAK. However, the most effective in the improvement and maintenance of carotid patency and in arterial thrombus mass reduction was SAK-RGD-K2. In contrast, all r-SAK derivatives reduced venous thrombus weight significantly in comparison to r-SAK and r-Hir. However, the most observable decrease in thrombus weight was obtained after application of recombinant proteins containing the r-Hir.The bleeding time was significantly prolonged in the animals treated with proteins containing r-Hir at a dose of 1.0 mg/kg.There were no observable changes in plasma fibrinogen concentration.In conclusion,our findings show thrombolytic activity in intravenous bolus injection of the novel thrombolytic agent SAK-RGD-K2-Hir in rats.Although this protein compares favourably with r-SAK in rat venous thrombolysis, we were unable to confirm the beneficial effects of SAK-RGDK2- Hir over r-SAK and rt-PA in the carotid artery thrombolysis model. Furthermore, our results also suggest that SAKRGD- K2-Hir bears a risk of bleeding, but this may be true for higher doses.

You may also be interested in...

1.
Willem M. Lijfering1, Michiel Coppens2, Marlène H. W. van de Poel1, Saskia Middeldorp2, Karly Hamulyák3, Ivan Bank2, Nic J. G. M. Veeger1, Martin H. Prins4, Harry R. Büller2, Jan van der Meer1

Thromb Haemost 2007 98 2: 457-563

http://dx.doi.org/10.1160/TH07-02-0138

2.

M. L. van Montfoort (1), J. C. M. Meijers (1)

Thromb Haemost 2013 110 2: 223-232

http://dx.doi.org/10.1160/TH12-11-0803

3.

G. Ocak (1), C. Y. Vossen (1, 2), J. I. Rotmans (3), W. M. Lijfering (1), F. R. Rosendaal (1, 4), K. J. Parlevliet (5), R. T. Krediet (6), E. W. Boeschoten (7), F. W. Dekker (1), M. Verduijn (1)

Thromb Haemost 2011 106 6: 1046-1052

http://dx.doi.org/10.1160/TH11-06-0422